รายงานฉบับนี้เป็นการนำเสนอผลการปฏิบัติงานที่เป็นเลิศหรือที่เรียกกันในภาษาอังกฤษว่า Best practice ในเรื่องของรูปแบบการให้บริการสารทดแทนเมทาโดนในชุมชน กรณีตัวอย่างในชุมชนสันติคีรี ตำบลแม่สลองนอกอำเภอแม่ฟ้าหลวง
Prepared by O-zone and PSI Thailand Foundation, this report presents the outcomes of the project’s best practice in providing a community-level MMT model.
From July 2009 to December 2014 the CHAMPION-IDU project operated as a critical component of Thailand’s national response to HIV among people who inject drugs.
Gloria Lai (IDPC) argumenta que a sociedade civil precisa defender e ajudar a facilitar um diálogo mais aberto e racional junto aos governos para incentivá-los a avaliar honestamente a atual abordagem.
Gloria Lai, IDPC Senior Policy Officer, argues that civil society must advocate for, and help facilitate, a more open and rational dialogue with governments to encourage them to engage in an honest assessment of the current drug control approach in Asia.
The EMCDDA describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events.
CELS highlights the different strategies used in countries across the Americas to tackle the drugs problem. It discusses the prohibitionist approach which has led to militarisation, violence, criminalisation of drug use, mass incarceration and forced crop eradication campaigns.
This WOLA/AIN report recognises Bolivia's efforts in reducing coca, working with farmers and providing alternative livelihoods, but concludes that the country’s outdated drug law remains unjust and continues to rely on disproportionate punishment for low-level, non-violent drug offences.
This workshop raised awareness and understanding of the nature of the drug problem in West Africa and called on the media to collaborate with civil society organisations to end the effects of bad drug policies on human rights and public health.
This IDPC advocacy note offers analysis and recommendations to contribute to the development of a post- 2015 ASEAN drug strategy that can meet the expectations of the ASEAN Secretary-General in being innovative, prompt to adapt to changing and challenging circumstances, and global in its outlook.
